SCM
XLO icon

Stonepine Capital Management’s Xilio Therapeutics XLO Stock Holding History

Stonepine Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$540K Buy
64,162
+55,143
+611% +$452K 0.22% 56
2025
Q4 		$80.8K Buy
+9,019
New +$94.7K 0.06% 64

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Stonepine Capital Management's XLO Position: Q1 2026 in Review

Stonepine Capital Management increased its Xilio Therapeutics (XLO) stake by 611% in Q1 2026, buying an estimated $452K and bringing the position to 64,162 shares worth $540K. The position accounts for 0.22% of the portfolio, ranked #56.

Stonepine Capital Management first reported a position in XLO in Q4 2025 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Stonepine Capital Management held 64,162 shares of Xilio Therapeutics worth $540K as of Q1 2026.
  • Stonepine Capital Management bought 55,143 Xilio Therapeutics shares in Q1 2026, an estimated $452K.
  • Xilio Therapeutics made up 0.22% of Stonepine Capital Management's portfolio in Q1 2026, its #56 holding.
  • Stonepine Capital Management first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.